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Less Is More*John A. Bittl, MDT he conventional approach to treating bifur-cation lesions has involved either a provi-sional single-stent strategy or intentional
stenting of both the main branch (MB) and the side
branch (SB). Because neither the “simple” provisional
strategy nor the “complex” multistent approach gua-
rantees SB access or optimal SB scaffolding, dedicated
bifurcation stents have been developed.
The Tryton Side Branch Stent (Tryton Medical,
Inc., Durham, North Carolina) is a non–drug-eluting
stent containing 3 zones designed to facilitate the
treatment of bifurcation lesions: an SB zone that
protrudes up to 6.5 mm into the SB, a transition zone
to cover the carina, and an MB zone with limited
scaffolding. Because this bifurcation stent requires
recrossing into the MB to implant a drug-eluting stent
and lock the device in place (1), its use falls into the
“complex” category of approaches for treating bifur-
cation lesions.SEE PAGE 533In this issue of the Journal, Généreux et al. (2)
report the highly anticipated results of the TRYTON
(Prospective, Single Blind, Randomized Controlled
Study to Evaluate the Safety & Effectiveness of the
Tryton Side Branch Stent Used With DES in Treatment
of de Novo Bifurcation Lesions in the Main Branch &
Side Branch in Native Coronaries) bifurcation trial,
which compared a dedicated bifurcation stent with
provisional stenting for bifurcation lesions. The
trial, which randomized 704 patients with true
bifurcation lesions and used a noninferiority design,
had disappointing results. At 9 months, the primary*Editorials published in the Journal of the American College of Cardiology
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paper to disclose.endpoint of target vessel failure (death, target vessel
myocardial infarction [MI], or target vessel revascu-
larization) was 17.4% in the bifurcation stent group
compared with 12.8% in the provisional group, a
difference that exceeded the pre-speciﬁed non-
inferiority margin of 5.5%. Moreover, procedures
with the bifurcation stent were longer (71  33 min
vs. 57  33 min) and required more contrast (261  106
ml vs. 223  93 ml) than those involving provisional
stenting.
Favorable outcomes for the bifurcation stent
included a lower in-segment diameter stenosis in the
SB in the bifurcation stent group than in the provi-
sional group (31.6% vs. 38.6%). This result may have
occurred because 5.5 to 6.5 mm of the bifurcation
stent extended into the SB and may have allowed
more uniform strut apposition and carina support
than provisional stenting (1). Despite this, no differ-
ence in binary restenosis rates was seen at 9 months
(23% vs. 27%), and angiographic restenosis in either
the MB or SB occurred at similar rates in the bifurca-
tion stent and provisional groups (28% vs. 33%). The
investigators discuss the limitations of using older
technology based on a bare-metal platform and spec-
ulate whether a more contemporary design incorpo-
rating drug-eluting technology in the SB would have
changed the results. Other analyses suggest that the
planned use of a drug-eluting stent in the SB as part of
a complex multistent approach lowers restenosis but
increases the risk of stent thrombosis and MI (3).
When the TRYTON investigators planned the trial,
they expected target vessel failure rates of 11% in the
bifurcation stent group and 13% in the provisional
group, but observed rates of 17.4% and 12.8%,
respectively. A potential contributor to the worse
than expected outcomes in the bifurcation stent
group was the occurrence of more periprocedural MIs,
probably because the bifurcation stent was used
in smaller SBs than intended. The smallest version of
the bifurcation stent used in the trial required an SB
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545with a minimum diameter of 2.5 mm. Implantation of
an SB stent in a smaller SB than intended may have
led to dissection. Only 41% of the study population
met the entry criteria based on SB diameter ($2.25
mm by quantitative angiography and $2.50 mm by
visual estimate). Future analyses could address the
issues of MI deﬁnition and SB sizing.
Although most bifurcation lesions are straightfor-
ward to treat, it is sometimes difﬁcult to predict which
bifurcation lesions will be problematic. Patients with
diffuse disease in the SB present a greater challenge
than those with focal disease and have commonly
been excluded from randomized controlled trials (4).
The use of bailout SB stenting in the TRYTON study
in 3% of the bifurcation stent group and in 8% of the
provisional group (2) suggests, but does not prove,
that patients with extensive and bulky SBs were not
enrolled.
Because it is paramount to save the SB in every case,
the search for dedicated bifurcation stent systems will
continue. Other dedicated bifurcation stent systems,
such as the “ﬂower petal” technique (5), Axxess (Bio-
sensors International Group Ltd., Singapore) (6), and
Multi-Link Frontier (Guidant Corp., Santa Clara, Cali-
fornia) (7), have the potential advantage of maintain-
ing guidewire access to the SB throughout the
procedure. The ultimate role of these and other dedi-
cated bifurcation stents will require evidence from
randomized controlled trials.
In summary, the TRYTON investigators (2) are
commended for completing an important trial and
for describing how the results should be translated
into clinical practice. They state that provisional
stenting remains the preferred approach for most
bifurcation lesions. On the basis of these results,
the ﬂexibility of the provisional T-stent strategy
or T-stenting with a small protrusion into the MB
in the majority of bifurcation lesions will likelypredominate in current practice over an approach
using dedicated bifurcation stents or previous ap-
proaches using culotte, crush, or reverse-crush with
multiple stents (8).
Treatment of all bifurcation lesions requires a
minimum guide size of 6-F, even with the transradial
approach. This allows both the MB and the SB to be
wired and fully dilated, if necessary, before jailing the
SB wire behind the MB stent. If the SB requires
treatment for ﬂow-limiting dissection or abnormal
fractional ﬂow reserve, the distal strut should be
chosen for recrossing. Many excellent guidewires
(e.g., the Choice PT Extra Support [Boston Scientiﬁc,
Marlborough, Massachusetts], MiracleBros 3 [Abbott
Vascular, Abbott Park, Illinois], and Hi-torque Whis-
per [Abbott Vascular]) have eliminated the difﬁculty
of recrossing. Kissing balloon inﬂations are strongly
recommended for 1-stent procedures and are
mandatory for 2-stent procedures (8).
Stenting of bifurcation lesions requires prolonged
dual antiplatelet therapy. In patients who cannot
tolerate prolonged dual antiplatelet therapy or are
likely to receive a bare-metal stent for a bifurcation
lesion, the alternative of medical therapy or surgical
revascularization should be recommended.
Much progress has been made, and more than 1,000
papers have been published on the treatment of
bifurcation lesions since Colombo et al. (9) reported
the use of kissing stents more than 20 years ago. New
approaches that combine drug-eluting technology
with ﬂexibility in sizing and conformation—and a
minimalist philosophy—are needed to improve the
outcomes for bifurcation lesions.
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